Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a periodic financial report.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details a specific share transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of Ordinary Shares (Dividend Re-investment) |
| Instrument | Ordinary Shares of 25 pence each (ISIN: GB0009252882) |
| Transaction Price | £16.6781 |
| Volume | 25.592 shares |
| Transaction Date | July 14, 2016 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records a routine acquisition of shares by the CEO following the re-investment of dividends paid on July 14, 2016.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It is a statutory disclosure of an insider transaction.
Key Facts for Investor Verification
- Insider Activity: CEO Sir Andrew Witty acquired 25.592 shares via dividend re-investment.
- Transaction Price: The shares were acquired at £16.6781 per share.
- Dividend Context: The transaction was triggered by dividends paid to shareholders on July 14, 2016.
- Reporting Limitation: This filing does not contain quarterly or annual financial performance data.